Literature DB >> 23332227

Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation.

Sara Meade1, Paul Sanghera, Christopher McConkey, Jack Fowler, George Fountzilas, John Glaholm, Andrew Hartley.   

Abstract

PURPOSE: Previous studies of synchronous chemoradiation therapy have modeled the additional effect of chemotherapy as additional radiation therapy biologically effective dose (BED). Recent trials of accelerated versus conventional fractionation chemoradiation have cast doubt on such modeling. The purpose of this study was to identify alternative models. METHODS AND MATERIALS: Nine trials of platinum-based chemoradiation were identified. In radiation therapy-alone arms, the radiation therapy BED for tumor was calculated using standard parameters. In chemoradiation arms, 3 methods were used to calculate tumor BED (tBED): additional BED, addition of 9.3 Gy BED for tumor to the radiation therapy BED; zero repopulation, BED with no correction for repopulation; variable t(p) (the average doubling time during accelerated repopulation), values of t(p) 3-10 were used to examine a partial suppression of repopulation. The correlations between the calculated percentage change in tBED for each method and observed percentage change in local control were assessed using the Pearson product moment correlation.
RESULTS: Significant correlations were obtained for all 3 methods but were stronger with zero repopulation (P=.0002) and variable tp (t(p) = 10) (P=.0005) than additional BED (P=.02).
CONCLUSIONS: Radiobiological models using modified parameters for accelerated repopulation seem to correlate strongly with outcome in chemoradiation studies. The variable tp method shows strong correlation for outcome in local control and is potentially a more suitable model in the chemoradiation setting. However, a lack of trials with an overall treatment time of more than 46 days inhibits further differentiation of the optimal model. Crown
Copyright © 2013. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23332227     DOI: 10.1016/j.ijrobp.2012.11.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

2.  Tumour repopulation and the role of abortive division in squamous cell carcinomas during chemotherapy.

Authors:  L G Marcu
Journal:  Cell Prolif       Date:  2014-05-13       Impact factor: 6.831

3.  Predictive Model and Precaution for Oral Mucositis During Chemo-Radiotherapy in Nasopharyngeal Carcinoma Patients.

Authors:  Pei-Jing Li; Kai-Xin Li; Ting Jin; Hua-Ming Lin; Jia-Ben Fang; Shuang-Yan Yang; Wei Shen; Jia Chen; Jiang Zhang; Xiao-Zhong Chen; Ming Chen; Yuan-Yuan Chen
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

4.  Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions.

Authors:  Ekin Ermiş; Mark Teo; Karen E Dyker; Chris Fosker; Mehmet Sen; Robin Jd Prestwich
Journal:  Radiat Oncol       Date:  2015-09-23       Impact factor: 3.481

5.  Revised Modelling of the Addition of Synchronous Chemotherapy to Radiotherapy in Squamous Cell Carcinoma of the Head and Neck-A Low α/β?

Authors:  James Best; Charles Fong; Helen Benghiat; Hisham Mehanna; John Glaholm; Andrew Hartley
Journal:  Medicines (Basel)       Date:  2018-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.